1. Generics Bulletin
  2. >>Business
  3. >>Strategy

Teva: ‘We Have To Overachieve To Get Back Our Credibility’

CEO Francis Bullish, As Share Price Climbs High Ahead Of Two-Year Anniversary

 
• By Dean Rudge

Teva’s CEO Richard Francis has spoken candidly about the steps he has taken in order for Teva to reclaim its credibility, underpinned by the company’s ‘Pivot to Growth’ strategy.

SC1807_Market Growth_572387551_1200.jpg
• Source: Shutterstock

Teva feels its present and its recent past will be “valued far more than the distant past,” as its leader admitted the company was continuing to battle to regain “credibility” following years of stagnation and decline.

Appearing at the recent Sidley Healthcare Investment Conference 2024 in central London, the Israeli firm’s CEO, Richard Francis, was asked...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

Repurposed Generics For Rare Diseases: Janet Woodcock Proposes Shortcut

A Duke-Margolis working group is developing ideas to enable non-profit firms to seek US FDA approval for new indications for off-patent medicines. The former acting commissioner thinks citizen petitions might be the fastest route.

Kashiv Joins Forces With MS Pharma In MENA For Omalizumab

 
• By Dave Wallace

Kashiv BioSciences has struck a deal with MS Pharma to market its omalizumab biosimilar rival to Xolair in the MENA region.

Civica Pairs With Fresenius Kabi To Supply Stelara Biosimilar

 
• By Dave Wallace

US non-profit Civica has announced a partnership with Fresenius Kabi to supply a Stelara rival, revealing pricing details for its exclusive unbranded version of Kabi’s Otulfi biosimilar that will be available from the start of next year.

Who’s Hired? Rosemont Gains A Chairperson But Loses A CEO

 
• By Dave Wallace

In our latest roundup of off-patent industry appointments, we see management changes at UK liquids specialist Rosemont, a push into biosimilars from Korea’s Daewoong, and fresh appointments at firms including Meitheal, Celltrion, Accord, Alvotech, Civica and Centrient.

More from Business

Sandoz Streamlines More Trials As First-Half Biosimilars Sales Hit $1.5bn

 
• By Dave Wallace

Sandoz has revealed plans to streamline more biosimilar trials amid evolving regulatory moves towards minimizing the need for comparative efficacy studies. The disclosure was just one of many pipeline and portfolio updates provided as the firm delivered positive first-half results.

Amgen Stands Firm On IV Checkpoint Inhibitor Biosimilars

 
• By Dean Rudge

Amgen continues to advance its intravenous biosimilar programs for key immuno-oncology agents, including its ABP 234 biosimilar to Keytruda and ABP 206 biosimilar to Opdivo, despite growing interest in subcutaneous formulations enabled by hyaluronidase technology.

Aurobindo Expects Lannett Acquisition To Pass FTC Scrutiny; Q1 US Revenue Falls

 
• By Vibha Ravi

Aurobindo is confident its planned Lannett acquisition will pass US FTC scrutiny after an attempt to acquire Sandoz assets was called off in 2020 post a delay in approval. The deal could widen Aurobindo’s US manufacturing presence at a time when its US Q1 revenue saw a year-on-year decline.